27 results about "TB - Tuberculosis" patented technology

This invention discloses a device and its application for distinguishing between pneumonia and tuberculosis in children. By detecting S100A8 / A9 and determining the corresponding diagnostic threshold, this invention achieves rapid, sensitive, and specific differentiation between children with tuberculosis and normal children, as well as children with pneumonia caused by other pathogens. It provides a reliable basis for clinical auxiliary diagnosis, improves diagnostic efficiency and accuracy, avoids misdiagnosis and missed diagnosis, and can thus guide rational clinical treatment and improve patient prognosis.

This invention discloses miRNA biomarkers for the auxiliary diagnosis of tuberculosis and their applications. This invention claims protection for the use of substances for detecting miRNAs in serum exosomes in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of tuberculosis patients or for the diagnosis or auxiliary diagnosis of active pulmonary tuberculosis patients. The miRNAs are any one or any combination of the following five miRNAs: miR-28-3p, miR-193b-5p, miR-370-3p, miR-1246, and miR-2110. This invention also claims protection for the use of substances for detecting serum exosome miRNAs in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of latent tuberculosis infection. The miRNAs are any one or any combination of the following three miRNAs: let-7e-5p, let-7d-5p, and miR-140-5p. This invention lays the foundation for further development of rapid early diagnosis techniques and methods for tuberculosis.

The invention discloses a spinal tuberculosis auxiliary diagnosis method and system, and relates to the technical field of intelligent medical treatment. The method comprises the following steps: acquiring a spinal tuberculosis DR image to be diagnosed; performing a preprocessing operation on the DR image to reduce image noise and enhance a spine structure contrast; inputting the preprocessed DR image into a pre-trained spinal tuberculosis classification model to obtain prediction probability distribution and confidence evaluation of the spinal tuberculosis physical classification; inputting the preprocessed DR image into a pre-trained focus detection model to obtain spatial position positioning information of the spinal tuberculosis focus; and integrating the prediction probability distribution, confidence evaluation and spatial position positioning information to generate an auxiliary diagnosis report. Under the condition of low-quality DR images in primary hospitals, primary doctors can be assisted in improving the diagnosis accuracy and positioning precision of early spinal tuberculosis lesions.

The invention relates to a T cell intracellular factor composition and application thereof, the T cell intracellular factor composition is selected from multiple of CCL3, CCL4, IFN gamma and TNFa, and the expression levels of the CCL3, the CCL4, the IFN gamma and the TNFa in peripheral blood of active tuberculosis patients are obviously different. As the expression levels in the peripheral blood of the active tuberculosis patient are obviously different, different stages and health states of tuberculosis can be accurately distinguished, the accuracy and specificity of diagnosis are obviously improved, and a reliable basis is provided for clinical diagnosis.

This invention relates to the field of biological sample preservation technology, specifically to a room-temperature preservation solution for bacterial RNA from sputum samples of tuberculosis patients. Each 100 mL of the RNA preservation solution comprises the following ingredients: 2-5 g tris(hydroxymethyl)aminomethane, 0.5-1.3 g mucin digester, 20-30 g guanidine isothiocyanate, 0.1-0.3 g hexadecylpyridine chloride, 0.5-1.2 g ethylhexene dicysteine, 20-40 mL fixative, 1-5 g stabilizer, 0.1-0.5 g inorganic salt, 0.3-0.6 g surfactant, and 0.1-0.5 g preservative. The preservation solution provided by this invention can effectively liquefy sputum samples at room temperature, meeting the requirements for long-distance sample transportation. The RNA quality of sputum samples treated with the preservation solution of this invention is suitable for various subsequent molecular detection methods, possessing significant application value and promising prospects for widespread application.

A chrysin derivative and a composition for a treatment of tuberculosis containing the same are provided. In detail, a chrysin derivative compound represented by chemical formula 1,or a salt thereof, and a composition for a treatment of tuberculosis and inflammation containing the same as an active ingredient are provided. In chemical formula 1, at least one of R1 and R2 is hydrogen, and the other is a C1-6 hydroxyalkyl group or a C1-10 alkenyl group unsubstituted or substituted with one or more C1-10 alkyl groups

The invention relates to the technical field of biological medicines, and discloses application of an IGF1R (Insulin-like Growth Factor 1 Receptor) gene as an anti-tuberculosis target spot in treatment and / or diagnosis of tuberculosis. The IGF1R gene is related to the susceptibility of tuberculosis. The IGF1R gene is used for regulating a tumor-related pathway and a PI3K-Akt signal pathway, so that host-oriented anti-tuberculosis is realized. BEAS-2B cells are stimulated through PPD, it is proved that the IGF1R gene has susceptibility correlation with TB, the correlation between the IGF1R gene and a tumor-related pathway and a PI3K-Akt signal pathway and related key functional genes are determined, a new thought is provided for research on TB morbidity and tuberculosis susceptibility, and a foundation is laid for the IGF1R gene serving as a new target in TB diagnosis and treatment.

The application belongs to the technical field of medical diagnosis, and specifically discloses a diabetes mellitus combined with tuberculosis marker and application thereof. It is found for the first time that the transcription level and protein level of activin A receptor 2A (ACVR2A), angiostatin and chemokine ligand 14 (CXCL14) are inversely proportional to the severity of diabetes mellitus combined with tuberculosis, and can be used as a diabetes mellitus combined with tuberculosis marker to indirectly reflect whether the crowd is suffering from diabetes mellitus combined with tuberculosis and the development of the disease, so as to timely diagnose and treat. A new diabetes mellitus combined with tuberculosis detection kit can be prepared according to the three markers, and is applied to public medical treatment. The three markers can effectively improve the diagnosis efficiency of diabetes mellitus combined with tuberculosis, and have high sensitivity and strong specificity.

This invention provides the use of SE-DR (HLA-DR molecule containing a co-epitope) affinity peptides for the preparation of drugs to treat rheumatic diseases in rheumatoid arthritis patients who are tuberculosis-positive and / or have hepatitis B. [Solution] The present invention provides a pharmaceutical composition comprising an SE-DR affinity peptide and a non-antigen-specific antirheumatic drug, and the use thereof for the preparation of drugs for the treatment of various types of rheumatic diseases. The pharmaceutical composition can rapidly inhibit the progression of rheumatic diseases and achieve sustained remission even after tapering or discontinuation of the drug, for complete control of rheumatic diseases.

Disclosed herein is a method of treating cachexia in a subject. According to some embodiments of the present disclosure, the method includes administering to the subject an effective amount of a recombinant antibody or a fragment thereof, which exhibits a binding affinity and a neutralizing effect on parathyroid hormone-related protein. According to certain embodiments of the present disclosure, the cachexia is caused by a parathyroid hormone-related protein (PTHrP)-expressing cancer, chronic kidney disease, kidney failure, heart failure, or tuberculosis.

The invention discloses a combined marker for risk assessment of active tuberculosis and application of the combined marker. The combined marker comprises interleukin 6, a chemotactic factor ligand 9, a chemotactic factor ligand 10 and a vascular endothelial growth factor. According to the disclosure, the combined marker for evaluating the risk of active tuberculosis of the subject and the application thereof can be provided.

Prophylaxis, immune therapy and vaccine strategies for Covid-19 variants and comorbid conditions such as aging, diabetes, cancer, tuberculosis or HIV. In one mode of invention, the role of the C3 Amplification loop is defined and how it derails the SNS functions or immune function at fluid and tissue levels. The plasticity in subverting C3 amplification control mechanism contribute to survival strategies of SARS-CoV-2 that contributes to various variants that can be reactivated at any stage of life based on immune system of patient that may get compromised with comorbid diseases such as aging, diabetes, cancer and HIV. Therapeutic modulation takes into consideration plasticity of different patient needs and their comorbid conditions by developing varying formulation methods and its combination approaches.

The application discloses application of lncRNA PRDM7-1:2 as a marker in development of a tuberculosis patient screening reagent. The application provides application of a substance for detecting lncRNA PRDM7-1:2 or a characteristic fragment of lncRNA PRDM7-1:2 in preparation of a kit for screening tuberculosis patients or in preparation of a kit for diagnosing or assisting in diagnosing tuberculosis. The inventors have carried out whole genome RNA chip screening, completed lncRNA spectrum screening and comparative analysis in PBMCs from two types of people, i.e. tuberculosis patients and healthy people, and preliminarily obtained a large number of differentially expressed lncRNAs. The inventors have carried out qPCR verification on the preliminarily obtained lncRNAs in another independent sample, and screened two lncRNAs. The inventors have analyzed the performance of the two lncRNAs as separate markers in a new population. The application is very important for rapid diagnosis of tuberculosis and early treatment.

Use of nintedanib or a medicinal salt thereof for the manufacture of a drug for treating tuberculosis, wherein the nintedanib or a medicinal salt thereof is used in combination with another antituberculous drug to treat tuberculosis or as an adjunct to tuberculosis treatment, the other antituberculous drug being selected from rifampicin, isoniazid, pyrazinamide, ethambutol, fluoroquinolones, streptomycin, kanamycin, amikacin, capreomycin, sodium 4-aminosalicylate, ethionamide, cycloserine, clofazimine, and linezolid.

Provided are a BCG recombinant strain ΔBCG_1820 in which BCG_1820 gene is knocked out, a preparation method therefor, and the use thereof in preparing a tuberculosis vaccine. The BCG recombinant strain ΔBCG_1820 can induce macrophages to produce more antibacterial peptides, so as to endow a host with a stronger capability to resist tubercle bacillus infection, and has the potential to be a candidate vaccine for tubercle bacillus.

This invention belongs to the field of biotechnology, specifically relating to a biomarker for diagnosing immunosuppressive status in chronic tuberculosis and its application. The biomarker is arginase-1. This invention demonstrates that serum Arginase-1 levels are significantly elevated in the progression of chronic tuberculosis, and are significantly positively correlated with the enrichment ratio of myeloid-derived suppressor cells and the expression levels of T cell exhaustion markers. As a key effector molecule of MDSCs, high expression of Arginase-1 reflects abnormal arginine metabolism and T cell exhaustion caused by MDSC amplification, making it an ideal indicator for assessing the immunosuppressive microenvironment in chronic tuberculosis. Using the biomarker of this invention, serum samples can be detected by simple methods such as ELISA, enabling rapid diagnosis, stratification, and dynamic monitoring of the immune status of patients with chronic tuberculosis.

The invention discloses a tuberculosis image detection method and system based on oversampling and transfer learning, and a medium, and belongs to the technical field of tuberculosis image detection. The method comprises the following steps: S1, training a plurality of deep neural network models by adopting a tuberculosis image data set, and carrying out different preprocessing and standardization operations on the tuberculosis image data set for different deep neural network models to obtain a first data set; s2, performing oversampling on the first data set by adopting an SMOTE algorithm to obtain a second data set; s3, constructing a prediction model through transfer learning and a plurality of trained deep neural network models, and training the prediction model by using the second data set to obtain a trained prediction model; and S4, inputting a to-be-detected tuberculosis image into the trained prediction model to obtain a prediction result. The tuberculosis image data is enhanced by introducing an oversampling technology, the proportion of positive and negative samples is balanced, and classification deviation caused by data imbalance is avoided.

The application belongs to the technical field of biology and particularly relates to screening and application of a urine metabolic marker of tuberculosis. The urine metabolic marker comprises 19 kinds of metabolites. After verification, it is proved that the level change of the 19 kinds of metabolites is indeed related to pulmonary tuberculosis. When the AUC value of one or more of the markers is greater than 0.8, it indicates that the patient is a pulmonary tuberculosis patient. The application further provides a screening method of a pulmonary tuberculosis metabolic marker, a detection kit for diagnosing pulmonary tuberculosis and a model for diagnosing pulmonary tuberculosis. The 19 kinds of urine metabolic markers screened by the application have high accuracy in pulmonary tuberculosis detection and are of great significance for the diagnosis of pulmonary tuberculosis.

This invention relates to the field of biomedical technology, and provides CD177. + Application of granulocyte subsets in the preparation of kits for the auxiliary diagnosis of tuberculosis. The CD177... + Granulocyte subsets include CD177 + Neutrophils and CD177 + Low-density granulocytes; the kit detects CD177. + The proportion of neutrophil-positive cells and CD177 + The mean fluorescence intensity of low-density granulocytes aids in the diagnosis of tuberculosis. This invention utilizes CD177. + Granulocyte subsets, as biomarkers, play an important role in auxiliary diagnosis, disease activity monitoring, and improving diagnostic efficiency. Based on CD177... + The proportion of neutrophil-positive cells, CD177 + By using the mean fluorescence intensity of low-density granulocytes, the ratio of neutrophils to lymphocytes, the ratio of platelets to lymphocytes, and the systemic inflammatory index, a predictive model for the auxiliary diagnosis of tuberculosis can be constructed. This model can more accurately identify true tuberculosis patients and effectively exclude non-patients, reducing the risk of misdiagnosis and missed diagnosis.

This invention relates to a composition and method for the detection of Tuberculosis drug resistance by multiplex small amplicon based, targeted Next-Gen sequencing (tNGS) using ribonucleotide bases in the primers. It also provides a bioinformatic data analysis tool, for the prediction of drug resistance / susceptibility towards anti- tuberculosis therapy drugs. The invention provides an efficient, cost-effective solution for identifying drug resistance / susceptibility right after tuberculosis diagnosis. In addition, a short read NGS platform with massive parallel sequencing, along with data analysis of this invention, offers high sensitivity and specificity for detection of drug resistance.

Compositions comprising a nucleic acid molecule that encodes TB proteins are disclosed. Methods of inducing an immune response against TB in an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed.

The invention discloses a multi-dimensional space-time prediction system and method based on a quantum fusion architecture, and belongs to the technical field of artificial intelligence and quantum computing crossing. According to the system, ten quantum heuristic models such as TFT-Net, WaveNet, ResNet, Attn-LSTM, GNN and QNN are creatively integrated, a PIMV-E quantum fusion algorithm is proposed, and high-precision space-time prediction in the fields of public health, environmental change and the like is realized through core technical means such as multi-dimensional feature engineering construction, adaptive weight temperature control adjustment and related redundancy elimination optimization. The system is provided with functional modules of time-point-by-time confidence band visualization, quantum performance thermodynamic diagram analysis, RESTfulAPI service and the like, and experimental verification shows that compared with a traditional method, the prediction precision is improved by 15%-25%, the trend capture capability reaches 92%, the anomaly detection sensitivity reaches 95%, and the average decision coefficient (R) is 0.89-0.92. The method can be widely applied to scenes such as tuberculosis incidence prediction, air pollution concentration early warning and chronic disease death risk assessment, and provides powerful technical support for decision making in related fields.

This invention discloses the application of lncRNA 046173 as a biomarker in the development of screening reagents for tuberculosis patients. The invention provides the application of substances for detecting lncRNA 046173 or characteristic fragments of lncRNA 046173 in the preparation of kits for screening tuberculosis patients, and in the preparation of kits for diagnosing or assisting in the diagnosis of tuberculosis. The inventors conducted whole-genome RNA microarray screening, completing the screening and comparative analysis of lncRNA profiles from PBMCs of both tuberculosis patients and healthy individuals, initially obtaining a large number of differentially expressed lncRNAs. The initially obtained lncRNAs were validated by qPCR in another independent sample group, screening out two lncRNAs. The inventors analyzed the performance of the two lncRNAs as individual biomarkers in a new population. This invention is of great importance for the rapid diagnosis and early treatment of tuberculosis.

This document provides methods and materials for targeting C-C chemokine receptor-like 2 (CCRL2) in a subject (e.g., a mammal). For example, methods and materials provided herein can be used to treat a condition that involves the overexpression of CCRL2 such as, without limitation, a cancer (e.g., myelodysplastic syndrome or acute myeloid leukemia) or tuberculosis. Treatment can include administering an anti-CCRL2 antibody, an antibody-drug conjugate, a chimeric antigen receptor T cell, or combinations thereof.

The invention discloses a sputum suction device for tuberculosis nursing, and relates to the technical field of medical instruments, the sputum suction device for tuberculosis nursing comprises an atomization machine, and the top end of the atomization machine is provided with a sputum suction assembly and a humidification assembly; the sputum suction assembly comprises a limiting fixing shell fixedly connected to the top end of the atomization machine, a liquid collecting box is installed in the limiting fixing shell in an inserted mode, an installation frame is fixedly arranged on the upper surface of the limiting fixing shell, and a sputum suction device is fixedly arranged on the upper surface of the installation frame. According to the negative pressure sputum suction device, the sputum suction assembly is arranged, the two negative pressure air suction cavities, the matched piston discs, the movable push rod and other assemblies are utilized, under driving of the driving motor, the linkage disc and the linkage rod can drive the two piston discs to alternately move up and down, continuous negative pressure sputum suction is achieved, interruption of single-time sputum suction is avoided, and the sputum suction continuity is improved. The sputum suction head adopts the spherical design and is provided with a plurality of sputum suction holes, and the sputum suction head can be in contact with a sputum area more comprehensively in cooperation with directional flow guide of the sputum suction catheter, so that the sputum suction effect is enhanced.

This invention relates to the field of nanobiosensing technology, and particularly to a method for preparing a multifunctional nanozyme probe and its application in tuberculosis and HIV comorbidities. The nanozyme probe comprises a covalent organic framework (COF) material as a carrier substrate, and first and second noble metal nanoparticles loaded on the surface of the carrier substrate. The first noble metal nanoparticles enhance the Raman signal of the carrier substrate, and the second noble metal nanoparticles provide enzyme activity. This nanozyme probe possesses excellent colorimetric response performance, peroxidase-like activity, and strong SERS performance, making it suitable as a multifunctional signal probe. When applied to bidirectional lateral flow immunochromatography (LFIA), by modifying it with specific antibodies against tuberculosis and HIV biomarkers, simultaneous and bidirectional detection of TB and HIV biomarkers can be achieved. This test strip supports three detection modes: visual colorimetry, catalytic amplification colorimetry, and precise SERS quantification, improving the sensitivity, dynamic range, and reliability of the detection.

The invention concerns a compound of formula (Ia) or (Ib) wherein R1 is hydrogen or a methyl group; R2 is an unsubstituted or substituted alkyl group; R3 is an aryl group or a heteroaryl group, optionally substituted by one or more groups selected from halogen, alkyl or alkoxy; and, in Formula (Ia), X is CH or N and Y is NH, S or O, or, in Formula (Ib), X is NH, S or O and Y is CH or N. The invention further concerns a method of synthesizing the inventive compound, a composition comprising the inventive compound or a pharmaceutically acceptable salt thereof and bedaquiline (BDQ), an analogue of bedaquiline (BDQ) or a mixture thereof, and the use of said composition or compound for the treatment of tuberculosis.